Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat form of leukemia. The results of Alliance A041703 Cohort 1, published in the Journal of Clinical Oncology, focused on treating patients aged 60 years and older with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) with immunotherapy medications inotuzumab ozogamicin and blinatumomab. Historically, this group has faced poor outcomes with traditional chemotherapy due to high rates of treatment-related death and relapse.

Trains move through the world’s subway stations in a consistent pattern: arriving, stopping, and moving to the next stop—and repeated by other trains throughout the day. A new study by a team of NYU psychology and linguistics researchers finds that our brains work much the same way when processing several words at once—as we routinely do when listening to others speak.